
There are about 27.8 ✘&;million people with hearing disa→"∞bilities in China, account♣₽ing for 33%of the total number of pλ§↕eople with disabilities, and th•¶±e proportion of newborndeafness is about ∞↕₩®;1-3%. More than 30,000 ne★✔δw deaf children are born $ each year, with more tha₩≤↕γn 60%of the genetic factor£₽s causing 3 deafness ≈∏. Environmental factors (about ↕<20%),unknown factors (about&nφ ♠σbsp;20%),in the normalpopulation, deaf gene'↓≈ mutation carriers more tha♠≤±n 80 million ≠↕↔people. A large number of patients w ith late hearing loss are d♣↓eaf engenedeaf by the←★ ir own genetic defects,∏Ω or by genetic defects and polymorphism, resulti'α☆♠ng in sensitivity to deafening e♥σnvironmental factors, and thus diφ&sease-causing. The traditional β∏♦αdetection method can not detλλ→↑ect the deafness caused by late deafne>ss or gene mutation in time, '→β✘and the testing of deafness can pl€σay the effect of early diagnσφ♥&osis, early detection and early inter§≤≤•vention.
High sensitivity:the detection limit of the genomic DNA of tα←he examinee is 2ng / μL δ★;
High accuracy: verified by 5000 multi-center clinical σβφsamples, the conformi≥ ty rate with sequencing is 100%;
Authoritative institu←÷σtion clinical verification:
Obstetrics, Neonatal |
Gynecologic |
Otolaryngology ≠← |
Internal Medicine, Surgery ∑≈ |
Neonatal |
Pre-pregnancy, early pr÷§♠egnancy women |
Hearing-impaired patients and their™Ω★ families |
Users of amino glycoside drugs ♣™∞ |
Early detection of congenital dφ eafness, late-onstage deafness and drug deafness,±♥₹ early diagnosi→★s, early prevention, early intervention £→± |
Screening carriers©σ of deaf engene mutations to provide genetic counselling&nb↔♣<™sp; and guidance for birth defec₽∑ ts |
Hearing-impaired family marriage guidance ☆δ← and medicatioα≈n guidance, prediction of cochlear implant effect |
Guidance on the use of antibiotics in ☆¥¶→; aminoglycoside drugs to pr±₽event drug deafness |
Normal (N/N)
35N● |
176N● |
235N● |
299N● |
538N● |
1494N● |
1555N● |
IVS7-2N● |
1226/1229N● |
2162/2168N● |
Number |
35M |
176M |
235M |
299M |
538M |
1494M |
1555M |
IVS7-2M |
1226M |
2168M |
|
167M |
281M |
589M |
IVS15+5M |
547M |
1975M |
2027M |
1174M |
1229M |
2162M |
Single-mutation pure ↓×hejuno(IVS7-2M)
35N● |
176N● |
235N● |
299N● |
538N● |
1494N● |
1555N● |
IVS7-2N |
1226/1229N● |
2162/2168N● |
Number |
35M |
176M |
235M |
299M |
538M |
1494M |
1555M |
IVS7-2M● |
1226M |
2168M |
|
167M |
281M |
589M |
IVS15+5M |
547M |
1975M |
2027M |
1174M |
1229M |
2162M |
Single Mutant Heoco(35M/N)
35N● |
176N● |
235N● |
299N● |
538N● |
1494N● |
1555N● |
IVS7-2N● |
1226/1229N● |
2162/2168N● |
Number |
35M● |
176M |
235M |
299M |
538M |
1494M |
1555M |
IVS7-2M |
1226M |
2168M |
|
167M |
281M |
589M |
IVS15+5M |
547M |
1975M |
2027M |
1174M |
1229M |
2162M |
Test specimen: Anticoagulant whole ≈><δblood sample
Technical principle:PCR - reve ≠←rse point hybridization
Packing size:25 test / kit
Class: In vitro diagnostic ®♠"reagents
Applicable instrumen♥"¶δts: common gene amplification✘& instrument, molecular hybridizer>♥
Date:2020-03-26
Date:2020-03-30
Date:2020-03-17
Date:2020-03-11
Date:2020-03-03